Ozmosi | KYLO-12 Drug Profile

Product Description

Mechanisms of Action: APOC3 Inhibitor

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Xiamen Ganbaoli Biopharmaceutical Co., Ltd.
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KYLO-12

Countries in Clinic: China

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Dyslipidemia|Hypertriglyceridemia

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT06783881	Kylo-12-I-C01	P1	Active, not recruiting	Hypertriglyceridemia	2026-02-17	50%	2025-09-19
CTR20250119	CTR20250119	P1	Recruiting	Dyslipidemia	None		2025-06-22	Patient Enrollment\|Treatments

Recent News Events

Date	Type	Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

KYLO-12

Alternative Names: KYLO-12, KYLO 12, KYLO12 Clinical Status: Active Latest Update: 2025-09-18 Latest Update Note: Clinical Trial Update